The DOI matches its Crossref record.
Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent
Open accessAbstract
The relative in vitro antiviral activities of three related nucleoside carboxamides, ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), and selenazole (2-beta-D-ribofuranosylselenazole-4-carboxamide), were studied against selected DNA and RNA viruses. Although the activity of selenazole against different viruses varied, it was significantly more potent than ribavirin and tiazofurin against all tested representatives of the families Paramyxoviridae (parainfluenza virus type 3, mumps virus, measles virus), Reoviridae (reovirus type 3), Poxviridae (vaccinia virus), Herpes-viridae (herpes simplex virus types 1 and 2), Togaviridae (Venezuelan equine encephalomyelitis virus, yellow fever virus, Japanese encephalitis virus), Bunyaviridae (Rift Valley fever virus, sandfly fever virus [strain Sicilian], Korean hemorrhagic fever virus), Arenaviridae (Pichinde virus), Picornaviridae (coxsackieviruses B1 and B4, echovirus type 6, encephalomyocarditis virus), Adenoviridae (adenovirus type 2), and Rhabdoviridae (vesicular stomatitis virus). The antiviral activity of selenazole was also cell line dependent, being greatest in HeLa, Vero-76, and Vero E6 cells. Selenazole was relatively nontoxic for Vero, Vero-76, Vero E6, and HeLa cells at concentrations of up to 1,000 micrograms/ml. The relative plating efficiency at that concentration was over 90%. The effects of selenazole on viral replication were greatest when this agent was present at the time of viral infection. The removal of selenazole from the medium of infected cells did not reverse the antiviral effect against vaccinia virus, but there was a gradual resumption of viral replication in cells infected with parainfluenza type 3 or herpes simplex virus type 1 (strain KOS). However, the antiviral activity of ribavirin against the same viruses was reversible when the drug was removed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
C-Nucleosides: Synthetic Strategies and Biological Applications
Hocek, M. (2009) · Chemical Reviews · doi:10.1021/cr9002165 · Cited by 383
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections
Baker, R. O., Bray, M., & Huggins, J. W. (2003) · Antiviral Research · doi:10.1016/s0166-3542(02)00196-1 · Cited by 279
Self-citationSAIJO, M., MORIKAWA, S., FUKUSHI, S., MIZUTANI, T., HASEGAWA, H., NAGATA, N., IWATA, N., & KURANE, I. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.01.003 · Cited by 82
Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial
Krogvold, L., Mynarek, I. M., Ponzi, E., Mørk, F. B., Hessel, T. W., Roald, T., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02576-1 · Cited by 55
Mynarek, I. M., Krogvold, L., Mørk, F. B., Lawaetz, T. W. H., Roald, T., Fagerland, M. W., Lindblom, N., Westman, J., Barker, P., Hyöty, H., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2121 · Cited by 4
Metadata
- Authors
- Kirsi, J. J., North, J. A., McKernan, P. A., Murray, B. K., Canonico, P. G., Huggins, J. W., Srivastava, P. C., & Robins, R. K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1983-09
- Volume
- 24
- Issue
- 3
- Pages
- 353-361
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2048726074
- Cited by
- 163
- References
- 0
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. https://app.cochat.ai/papers/10.1128/aac.24.3.353
- The paper
- Kirsi, J. J., North, J. A., McKernan, P. A., Murray, B. K., Canonico, P. G., Huggins, J. W., Srivastava, P. C., & Robins, R. K. (1983). Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.24.3.353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.